Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors

Lobaina, Yadira; Chen, Rong; Ai, Panchao; Lei, Yang; Alvarez‐Lajonchere, Liz; Suzarte, Edith; Tan, Changyuan; Silva, Ricardo; Jiang, Zhongshan; Yang, Ke; Perera, Yasser; Hermida, Lisset

doi:10.1089/vim.2022.0186

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human sera from COVID-19 convalescent (N = 10) and negative (N = 10) individuals were obtained by the team from Guangdong Eighth People’s Hospital. Samples were collected as part of a study approved by the Institutional Ethics Committee from the Eighth People’s Hospital of Dongguan (Guangdong Province, China) as previously reported [ 23 ]. Informed written consent was obtained from each participant before enrolment in the study.…”

Section: Methodsmentioning

confidence: 99%

A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response

Lobaina,

Chen,

Suzarte

et al. 2024

Vaccines

Self Cite

View full text Add to dashboard Cite

A chimeric protein, formed by two fragments of the conserved nucleocapsid (N) and S2 proteins from SARS-CoV-2, was obtained as a recombinant construct in Escherichia coli. The N fragment belongs to the C-terminal domain whereas the S2 fragment spans the fibre structure in the post-fusion conformation of the spike protein. The resultant protein, named S2NDH, was able to form spherical particles of 10 nm, which forms aggregates upon mixture with the CpG ODN-39M. Both preparations were recognized by positive COVID-19 human sera. The S2NDH + ODN-39M formulation administered by the intranasal route resulted highly immunogenic in Balb/c mice. It induced cross-reactive anti-N humoral immunity in both sera and bronchoalveolar fluids, under a Th1 pattern. The cell-mediated immunity (CMI) was also broad, with positive response even against the N protein of SARS-CoV-1. However, neither neutralizing antibodies (NAb) nor CMI against the S2 region were obtained. As alternative, the RBD protein was included in the formulation as inducer of NAb. Upon evaluation in mice by the intranasal route, a clear adjuvant effect was detected for the S2NDH + ODN-39M preparation over RBD. High levels of NAb were induced against SARS-CoV-2 and SARS-CoV-1. The bivalent formulation S2NDH + ODN-39M + RBD, administered by the intranasal route, constitutes an attractive proposal as booster vaccine of sarbecovirus scope.

show abstract

Section: Methodsmentioning

confidence: 99%

A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response

Lobaina,

Chen,

Suzarte

et al. 2024

Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, recent studies reported a possible cross-protective effect of pre-existing HCoV-infection immunity on subsequent SARS-CoV-2 infection and on the severity of COVID-19 outcome. 7 While there is no explicit report of sexual discordance in HCoV prevalence, it is becoming more evident that males of both younger and older ages are more susceptible to respiratory viruses in general and are also at a higher risk of severe disease outcomes when compared to females. 2 The reasons are not entirely clear, but several explanations have been proposed, including immunological, genetic, hormonal, and sociobehavioral factors.…”

Section: Introductionmentioning

confidence: 99%

“…Interest in these viruses has been recently renewed as they can be handled in reduced biosafety laboratory containment thus providing an alternative to SARS‐CoV‐2 for preclinical screening and antiviral design. Furthermore, recent studies reported a possible cross‐protective effect of pre‐existing HCoV‐infection immunity on subsequent SARS‐CoV‐2 infection and on the severity of COVID‐19 outcome 7 …”

Section: Introductionmentioning

confidence: 99%

The antiviral potential of the antiandrogen enzalutamide and the viral‐androgen signaling interplay in seasonal coronaviruses

Ogunjinmi,

Abdullahi,

Somji

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

The sex disparity in COVID‐19 outcomes with males generally faring worse than females has been associated with the androgen‐regulated expression of the protease TMPRSS2 and the cell receptor ACE2 in the lung and fueled interest in antiandrogens as potential antivirals. In this study, we explored enzalutamide, an antiandrogen used commonly to treat prostate cancer, as a potential antiviral against the human coronaviruses which cause seasonal respiratory infections (HCoV‐NL63, −229E, and ‐OC43). Using lentivirus‐pseudotyped and authentic HCoV, we report that enzalutamide reduced 229E and NL63 entry and infection in both TMPRSS2‐ and nonexpressing immortalized cells, suggesting a TMPRSS2‐independent mechanism. However, no effect was observed against OC43. To decipher this distinction, we performed RNA‐sequencing analysis on 229E‐ and OC43‐infected primary human airway cells. Our results show a significant induction of androgen‐responsive genes by 229E compared to OC43 at 24 and 72 h postinfection. The virus‐mediated effect on AR‐signaling was further confirmed with a consensus androgen response element‐driven luciferase assay in androgen‐depleted MRC‐5 cells. Specifically, 229E induced luciferase‐reporter activity in the presence and absence of the synthetic androgen mibolerone, while OC43 inhibited induction. These findings highlight a complex interplay between viral infections and androgen‐signaling, offering insights for disparities in viral outcomes and antiviral interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Furthermore, recent studies reported a possible cross-protective effect of preexisting HCoV-infection immunity on subsequent SARS-CoV-2 infection and on the severity of COVID-19 outcome. 7 While there is no explicit report of sexual discordance in HCoV prevalence, it is becoming more evident that males of both younger and older ages are more susceptible to respiratory viruses in general and are also at a higher risk of severe disease outcomes when compared to females. 2 The reasons are not entirely clear, but several explanations have been proposed, including immunological, genetic, hormonal and socio-behavioral factors.…”

Section: Introductionmentioning

confidence: 99%

The antiviral potential of the antiandrogen enzalutamide and the viral-androgen interplay in seasonal coronaviruses

Ogunjinmi,

Abdullahi,

Somji

et al. 2023

Preprint

View full text Add to dashboard Cite

The sex disparity in COVID-19 outcomes with males generally faring worse than females has been associated with the androgen-regulated expression of the protease TMPRSS2 and the cell receptor ACE2 in the lung and fueled interest in antiandrogens as potential antivirals. In this study, we explored enzalutamide, an antiandrogen used commonly against prostate cancer, as a potential antiviral against the human coronaviruses which cause seasonal respiratory infections (HCoV-NL63, -229E, and -OC43). Using lentivirus-pseudotyped and authentic HCoV, we report that enzalutamide reduced 229E and NL63 entry and replication in both TMPRSS2- and non-expressing immortalised cells, suggesting a TMPRSS2-independent mechanism. However, no effect was observed against OC43. To decipher this distinction, we performed RNA-sequencing analysis on 229E-and OC43- infected primary human airway cells. Our results show a significant induction of androgen-responsive genes by 229E compared to OC43 at 24 and 72h post-infection. The virus-mediated effect to AR signaling was further confirmed with a consensus androgen response element (ARE)-driven luciferase assay in androgen-depleted MRC-5 cells. Specifically, 229E induced luciferase reporter activity in the presence and absence of the synthetic androgen mibolerone, while OC43 inhibited induction. These findings highlight a complex interplay between viral infections and androgen signaling, offering insights for potential antiviral interventions.

show abstract

Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors

Cited by 6 publications

References 24 publications

A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response

A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response

The antiviral potential of the antiandrogen enzalutamide and the viral‐androgen signaling interplay in seasonal coronaviruses

The antiviral potential of the antiandrogen enzalutamide and the viral-androgen interplay in seasonal coronaviruses

Contact Info

Product

Resources

About